- Healthcare company BTG and Boston Scientific signed an agreement to sell its existing drug-eluting and bland embolic microsphere business to Varian Medical Systems.

The announced of the sale comes as Boston Scientific continued to make progress on its £3.3bn acquisition of BTG.

The acquisition had received merger control clearance in Germany under the German Act Against Restraints of Competition and the Taiwan Fair Trade Commission had terminated its investigation, the company said.

The acquisition of BTG by Bidco, would be implemented by means of a court-sanctioned scheme of arrangement, with the hearing slated for 15 August.

At 8:03am: [LON:BTG] BTG PLC share price was +2.25p at 836.75p

Story provided by